Literature DB >> 21321112

An early response transcription factor, Egr-1, enhances insulin resistance in type 2 diabetes with chronic hyperinsulinism.

Ning Shen1, Xiao Yu, Fei-Yan Pan, Xiang Gao, Bin Xue, Chao-Jun Li.   

Abstract

One of the most important characteristics of type 2 diabetes is insulin resistance, during which the patients normally experienced hyperinsulinism stress that would alter insulin signal transduction in insulin target tissues. We have previously found that early growth responsive gene-1 (Egr-1), a zinc finger transcription factor, is highly expressed in db/db mice and in the fat tissue of individuals with type 2 diabetes. In this report, we found that chronic exposure to hyperinsulinism caused persistent Erk/MAPK activity in adipocytes and enhanced insulin resistance in an Egr-1-dependent manner. An elevation in Egr-1 augmented Erk1/2 activation via geranylgeranyl diphosphate synthase (GGPPS). Egr-1-promoted GGPPS transcription increased Ras prenylation and caused Erk1/2 activation. The sustained activation of Erk1/2 resulted in the phosphorylation of insulin receptor substrate-1 at Serine 612. Phosphorylation at this site impaired insulin signaling in adipocytes and reduced glucose uptake. The loss of Egr-1 function, knockdown of GGPPS, or inhibition of Erk1/2 activity in insulin-resistant adipocytes restored insulin receptor substrate-1 tyrosine phosphorylation and increased insulin sensitivity. Our results suggest a new mechanism by which the Egr-1/GGPPS/Erk1/2 pathway is responsible for insulin resistance during hyperinsulinism. This pathway provides a new therapeutic target for increasing insulin sensitivity: inhibiting the function of Egr-1.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21321112      PMCID: PMC3077649          DOI: 10.1074/jbc.M110.190165

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  A dominant negative inhibitor of the Egr family of transcription regulatory factors suppresses cerebellar granule cell apoptosis by blocking c-Jun activation.

Authors:  Y Levkovitz; J M Baraban
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

2.  PTEN inhibits insulin-stimulated MEK/MAPK activation and cell growth by blocking IRS-1 phosphorylation and IRS-1/Grb-2/Sos complex formation in a breast cancer model.

Authors:  L P Weng; W M Smith; J L Brown; C Eng
Journal:  Hum Mol Genet       Date:  2001-03-15       Impact factor: 6.150

3.  The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling.

Authors:  T Virolle; E D Adamson; V Baron; D Birle; D Mercola; T Mustelin; I de Belle
Journal:  Nat Cell Biol       Date:  2001-12       Impact factor: 28.824

4.  Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle.

Authors:  K Cusi; K Maezono; A Osman; M Pendergrass; M E Patti; T Pratipanawatr; R A DeFronzo; C R Kahn; L J Mandarino
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

5.  Deletion of Gab1 in the liver leads to enhanced glucose tolerance and improved hepatic insulin action.

Authors:  Emilie A Bard-Chapeau; Andrea L Hevener; Shinong Long; Eric E Zhang; Jerrold M Olefsky; Gen-Sheng Feng
Journal:  Nat Med       Date:  2005-04-10       Impact factor: 53.440

6.  Angiotensin II increases leptin secretion by 3T3-L1 and human adipocytes via a prostaglandin-independent mechanism.

Authors:  Suyeon Kim; Jay Whelan; Kate Claycombe; David B Reath; Naima Moustaid-Moussa
Journal:  J Nutr       Date:  2002-06       Impact factor: 4.798

7.  Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action.

Authors:  Vincent Aguirre; Eric D Werner; Jodel Giraud; Yong Hee Lee; Steve E Shoelson; Morris F White
Journal:  J Biol Chem       Date:  2001-10-17       Impact factor: 5.157

8.  A central role for JNK in obesity and insulin resistance.

Authors:  Jiro Hirosumi; Gürol Tuncman; Lufen Chang; Cem Z Görgün; K Teoman Uysal; Kazuhisa Maeda; Michael Karin; Gökhan S Hotamisligil
Journal:  Nature       Date:  2002-11-21       Impact factor: 49.962

9.  Three mitogen-activated protein kinases inhibit insulin signaling by different mechanisms in 3T3-L1 adipocytes.

Authors:  Midori Fujishiro; Yukiko Gotoh; Hideki Katagiri; Hideyuki Sakoda; Takehide Ogihara; Motonobu Anai; Yukiko Onishi; Hiraku Ono; Miho Abe; Nobuhiro Shojima; Yasushi Fukushima; Masatoshi Kikuchi; Yoshitomo Oka; Tomoichiro Asano
Journal:  Mol Endocrinol       Date:  2002-12-05

10.  Grb10 inhibits insulin-stimulated insulin receptor substrate (IRS)-phosphatidylinositol 3-kinase/Akt signaling pathway by disrupting the association of IRS-1/IRS-2 with the insulin receptor.

Authors:  KeriLyn R Wick; Eric D Werner; Paul Langlais; Fresnida J Ramos; Lily Q Dong; Steven E Shoelson; Feng Liu
Journal:  J Biol Chem       Date:  2002-12-18       Impact factor: 5.157

View more
  34 in total

1.  GGPPS, a new EGR-1 target gene, reactivates ERK 1/2 signaling through increasing Ras prenylation.

Authors:  Ning Shen; Yue Shao; Shan-Shan Lai; Long Qiao; Run-Lin Yang; Bin Xue; Fei-Yan Pan; Hua-Qun Chen; Chao-Jun Li
Journal:  Am J Pathol       Date:  2011-10-06       Impact factor: 4.307

2.  Hepatic miR-181b-5p Contributes to Glycogen Synthesis Through Targeting EGR1.

Authors:  Shuyue Wang; Chen Liang; Huihan Ai; Meiting Yang; Jingwen Yi; Lei Liu; Zhenbo Song; Yongli Bao; Yuxin Li; Luguo Sun; Huiying Zhao
Journal:  Dig Dis Sci       Date:  2019-01-09       Impact factor: 3.199

3.  Biased TAS2R Bronchodilators Inhibit Airway Smooth Muscle Growth by Downregulating Phosphorylated Extracellular Signal-regulated Kinase 1/2.

Authors:  Donghwa Kim; Soomin Cho; Maria A Castaño; Reynold A Panettieri; Jung A Woo; Stephen B Liggett
Journal:  Am J Respir Cell Mol Biol       Date:  2019-05       Impact factor: 6.914

4.  4E-BPs Control Fat Storage by Regulating the Expression of Egr1 and ATGL.

Authors:  Maneet Singh; Yu-Kyong Shin; Xiaoqing Yang; Brad Zehr; Partha Chakrabarti; Konstantin V Kandror
Journal:  J Biol Chem       Date:  2015-03-26       Impact factor: 5.157

Review 5.  The balance of protein farnesylation and geranylgeranylation during the progression of nonalcoholic fatty liver disease.

Authors:  Yue Zhao; Tian-Yu Wu; Meng-Fei Zhao; Chao-Jun Li
Journal:  J Biol Chem       Date:  2020-03-05       Impact factor: 5.157

6.  Increased Expression of EGR-1 in Diabetic Human Adipose Tissue-Derived Mesenchymal Stem Cells Reduces Their Wound Healing Capacity.

Authors:  Nhu-Thuy Trinh; Toshiharu Yamashita; Kinuko Ohneda; Kenichi Kimura; Georgina To'a Salazar; Fujio Sato; Osamu Ohneda
Journal:  Stem Cells Dev       Date:  2016-04-22       Impact factor: 3.272

7.  Egr-1 decreases adipocyte insulin sensitivity by tilting PI3K/Akt and MAPK signal balance in mice.

Authors:  Xiao Yu; Ning Shen; Ming-Liang Zhang; Fei-Yan Pan; Chen Wang; Wei-Ping Jia; Chang Liu; Qian Gao; Xiang Gao; Bin Xue; Chao-Jun Li
Journal:  EMBO J       Date:  2011-08-09       Impact factor: 11.598

8.  Insulin inhibits lipolysis in adipocytes via the evolutionarily conserved mTORC1-Egr1-ATGL-mediated pathway.

Authors:  Partha Chakrabarti; Ju Youn Kim; Maneet Singh; Yu-Kyong Shin; Jessica Kim; Joerg Kumbrink; Yuanyuan Wu; Mi-Jeong Lee; Kathrin H Kirsch; Susan K Fried; Konstantin V Kandror
Journal:  Mol Cell Biol       Date:  2013-07-15       Impact factor: 4.272

9.  Lipid-induced Muscle Insulin Resistance Is Mediated by GGPPS via Modulation of the RhoA/Rho Kinase Signaling Pathway.

Authors:  Weiwei Tao; Jing Wu; Bing-Xian Xie; Yuan-Yuan Zhao; Ning Shen; Shan Jiang; Xiu-Xing Wang; Na Xu; Chen Jiang; Shuai Chen; Xiang Gao; Bin Xue; Chao-Jun Li
Journal:  J Biol Chem       Date:  2015-06-25       Impact factor: 5.157

Review 10.  Emerging roles of zinc finger proteins in regulating adipogenesis.

Authors:  Shengjuan Wei; Lifan Zhang; Xiang Zhou; Min Du; Zhihua Jiang; Gary J Hausman; Werner G Bergen; Linsen Zan; Michael V Dodson
Journal:  Cell Mol Life Sci       Date:  2013-06-13       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.